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Abstract 
Skin penetration and localisation of chlorhexidine digluconate (CHG) within the skin have been 
investigated in order to better understand and optimise the delivery using a nano polymeric delivery 
system of this topically-applied antimicrobial drug. Franz-type diffusion cell studies using in vitro 
porcine skin and tape stripping procedures were coupled with Time-of-Flight Secondary Ion Mass 
Spectrometry (ToF-SIMS) to visualise the skin during various treatments with CHG and 
polyamidoamine dendrimers (PAMAM). Pre-treatment of the skin with PAMAM dendrimers 
significantly increased the amount and depth of permeation of CHG into the skin in vitro. The effect 
observed was not concentration dependant in the range 0.5 – 10 mM PAMAM. This could be 
important in terms of the efficiency of treatment of bacterial infection in the skin. It appears that the 
mechanism of enhancement is due to the PAMAM dendrimer disrupting skin barrier lipid 
conformation or by occluding the skin surface. Franz-type diffusion cell experiments are 
complimented by the detailed visualisation offered by the semi-quantitative ToF-SIMS method which 
provides excellent benefits in terms of sensitivity and fragment ion specificity. This allows a more 
accurate depth profile of chlorhexidine permeation within the skin to be obtained and potentially 
affords the opportunity to map the co-localisation of permeants with skin structures, thus providing a 
greater ability to characterise skin absorption and to understand the mechanism of permeation, 
providing opportunities for new and more effective therapies. 
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INTRODUCTION 
 
 
Chlorhexidine (1,6-di(4-chlorophenyl-diguanido)hexane) (CHG) is a cationic bisbiguanide. It has a 
broad spectrum of antimicrobial activity and a low toxicity to mammalian cells [1]. It has been used 
extensively for the last sixty years in a range of formulations including water, ethanol and isopropyl 
alcohol based preparations. It has been used extensively in a range of topical formulations; however, 
its skin permeability has been shown to be poor. For example, while it was demonstrated that 
permeability from aqueous solutions was time-dependant, its overall permeation was limited, with 
the permeant accumulating mostly in superficial tissues of the skin and with no penetration across 
full-thickness skin being observed [2]. Similar results for permeation of CHG into and across rodent 
skin were reported elsewhere [3]. Such studies clearly indicate that the poor skin permeability of CHG, 
ostensibly due to its physicochemical properties (i.e. molecular weight of 897.8) and may allow 
potential pathogens to remain viable within deeper layers of the skin. 
 
One of the broader limitations of such studies, not just those confined to CHG, but to all potential 
percutaneous penetrants, is the analytical methodology employed to discern absorption into and 
across skin tissues. Tape stripping methods are limited by a lack of method standardisation, 
incomplete removal of the stratum corneum and inconsistent removal of skin layers [4,5]. While a 
number of studies [6 – 8] have suggested iterations to tape stripping methodology to alleviate such 
issues, it is a method that does not permit identification of the histological compartments within skin 
in which a permeant might reside. This extends to location of the compound of interest with the 
dermis or epidermis as the tape strips may overlap both of those regions. Furthermore, horizontal 
sectioning is a time-consuming and laborious process. 
 
Deposition and distribution of CHG on, and within, skin was recently characterised for the first time 
by Time-of-Flight Secondary Ion Mass Spectrometry (ToF-SIMS) [9]. ToF-SIMS imaging analysis 
involves the rastering of a pulsed primary ion beam over a surface of the tissue samples, leading to a 
collision cascade and the production of secondary ions [10]. Chemical maps of selected secondary ions 
can be retrospectively constructed for the area analysed {11]. ToF-SIMS analysis provides excellent 
sensitivity to the ppm range, including the parallel detection of isotopes and spatial localisation of 
permeants within tissue structures. The ToF-SIMS method therefore obviates the need for complex 
sample preparation or the use of radiolabelling. It therefore allows the distribution of a compound 
within a biological tissue to be mapped and may even yield information on the mechanisms 
underpinning such permeability and skin localisation. ToF-SIMS has been applied to analyse the skin 
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by a number of researchers to explore the effects of photo ageing on human skin and to characterise 
the distribution of synthetic pseudoceramides delivered from a cosmetic formulation [12 – 14].  Most 
recently, this method has been applied to the characterisation of age-related changes to human 
stratum corneum lipids following in vivo sampling, which identified alterations to the spatial 
distribution of a number of stratum corneum lipids associated with membrane stability [15].   
 
Classical in vitro Franz cell permeation studies have previously been combined with the ToF-SIMS 
analysis of skin. This combination of methods was used to characterise the distribution of CHG 
delivered from simple vehicles into skin, including the benchmarking of tape strips against the ToF-
SIMS method, where it was found that the ToF-SIMS method has a lower limit of detection than the 
tape stripping methods [9].  
 
A more comprehensive characterisation of CHG skin permeability was reported recently [16].  The 
authors presented both high mass resolution mass spectra and high spatial resolution images provided 
by ToF-SIMS from cryosectioned samples that followed a 24-hour application of CHG (2% w/w 
solution) to porcine skin in a Franz-type diffusion cell model. CHG distribution was mapped throughout 
the skin sections and confirmed that it was predominately localised within the stratum corneum. This 
was compared to ToF-SIMS analysis of tape strips which supported the distribution profile within the 
skin tissue. Thus, the ToF-SIMS methods demonstrated excellent complementarity to diffusion cell 
experiments and the ability to image samples with high chemical specificity without the need for 
radiolabels. The ToF-SIMS data allows for the visualisation of the drug deposition on each corneocyte 
layer of individual tape strips so that detailed permeation profiles of a drug throughout the stratum 
corneum can be obtained.   
 
Poly(amidoamine) (PAMAM) dendrimers have previously been used as percutaneous absorption 
enhancers for a number of topically applied therapeutics where they have demonstrated the ability 
to conjugate to drugs bound to their surface or to encapsulate drugs within their structure [17 - 22]. 
The properties exhibited by PAMAM dendrimers have allowed for the protection of degradable drugs, 
increased the aqueous solubility of drugs and have been shown to ameliorate modified drug release 
through thermo- or pH-responsive properties [23 – 25]. 
 
PAMAM dendrimers have also demonstrated the ability to act as transdermal drug carriers by 
facilitating skin permeation of 5-fluorouracil into porcine skin [26]. The G4-PAMAM-OH and G4-
PAMAM-NH2 dendrimers have been shown to enhance the permeation of indomethacin across skin in 
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vitro by a factor of 4.5, where the dendrimer formed a complex with indomethacin through 
electrostatic and hydrophobic bonding [27]. However, G4-PAMAM-NH2 dendrimers generally have a 
greater in vivo toxicity than the lower generation (G0-G2) PAMAMs i.e. smaller dendrimers with a 
lower molecular weight and fewer surface functionalities, limiting significantly their clinical 
applications.  
 
The aim of this present study is to evaluate the role of PAMAM dendrimers as enhancers of 
chlorhexidine permeation into and across porcine skin. As well as conventional Franz-type diffusion 
cell studies, including tape stripping of the stratum corneum, ToF-SIMS analysis of cryosectioned skin 
sections was performed to visualise the permeation and distribution of CHG within the skin. 
 
 
METHODS 
 
Materials 
The G3-PAMAM-NH2 dendrimer (Sigma Aldrich product code 412422, molecular weight 6909 Da, 
supplied in methanol for reasons of stability and diluted in water prior to use), chlorhexidine 
digluconate, sodium chloride, sodium octane-1-sulphonate, triethylamine, glacial acetic acid and 
optimal cutting temperature media were purchased from Sigma Aldrich (Dorset, UK). HPLC grade 
methanol and syringe filters 0.2 μm, 15 mm diameter polypropylene filters were purchased from 
Fisher Scientific, Loughborough, UK). The MetLab ODS-H reverse phase column (150 × 4.6 mm, 5 μm) 
and HPLC vials were purchased from Phenomenex (Cheshire, UK).  
 
In vitro percutaneous absorption in a porcine skin model 
 
Method overview 
Two types of skin preparation were used in this investigation. Epidermal membranes were prepared from 
whole pig ears by heat separation to study the absorption of CHG into the receptor fluid following PAMAM 
pre-treatment. In order to study the localisation of CHG in the different regions of the skin, using a tape 
stripping technique, whole pig skin samples from the flank were dermatomed to produce 400um split 
thickness samples, prior to mounting them in the Franz diffusion cells. Both methods of skin preparation are 
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permitted in OECD test guideline 428 for the assessment of dermal absorption in vitro. Thus, all 
investigations of percutaneous absorption using Franz-type diffusion cells described in this study were 
conducted according to the OECD method as discussed in detail elsewhere [9, 16]. Pig ears were 
obtained as a residue of food production (but not subject to steam cleaning), they were shaved, gently 
cleaned and the subcutaneous fat and cartilage was removed. The skin was prepared by heat 
separation and placed in Franz static diffusion cells. Skin barrier integrity was determined to be intact 
by measurement of transepithelial electrical resistance (TEER). An electrical resistance reading of ≥ 3 
KΩ has been previously shown to represent the normal barrier integrity of pig ear skin in the static 
diffusion cells used in this investigation [28 – 31]. 
 
The effect of PAMAM dendrimer pre-treatment on the in vitro permeation on CHG using porcine 
epidermis 
Physiological saline was used as the receptor phase in diffusion experiments as it provided adequate 
sink conditions for the penetrant. Briefly, 4.5 mL of physiological saline was added to the receptor 
chamber of each Franz cell. The Franz cells (n = 15 – 24; see Table 2) were placed in the water bath 
(32°C ± 1°C) on a submersible stirring plate for 30 minutes and allowed to equilibrate. Both a G3-
PAMAM-NH2 (0.5 mM-10 mM, diluted in MilliQ water) and a 2% (w/v) solution of CHG were prepared 
in distilled water from stock solutions of G3-PAMAM-NH2 (20% (w/v)) and CHG (20% (w/v)) 
respectively. 0.2 mL of G3-PAMAM-NH2 (0.5 mM-10 mM) was then applied to the skin surface for a 
24 h contact time. The vehicle was dosed without the presence of PAMAM dendrimer in the cells 
representing the controls. At the end of the exposure period, the PAMAM dendrimer was then washed 
from the skin surface by rinsing with 2 mL aliquots of distilled water (10 mL in total) pipetted over the 
surface of the dosed skin, taking care not to damage the skin surface. An infinite dose (1 mL) of the 
CHG solution (2% w/v) was then applied to the skin surface and left for a contact time of 24 h. At 
various time points during this 24 h period a 500 μL aliquot of receptor fluid was removed and replaced 
with fresh physiological saline. After 24 h, excess CHG was removed from the skin surface by further 
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washing. The skin sample was then removed from the diffusion chamber and the skin prepared for 
CHG extraction and subsequent HPLC analysis as described previously [16].  
 
Franz diffusion cell studies using porcine dermatomed skin for tape stripping. 
Additional Franz cells were dosed as described in the preceding section but the skin was also tape-
stripped at the end of the experiment using the gravimetric method reported previously [32] with a 
four-figure balance (Precisa, 262 SMA-FR, Milton Keynes, UK). Once 21 tape strips had been taken 
they were pooled together; tape strips 1-3 were analysed as individual tape strips. Tape strips 4-6, 7-
10, 11-16 and strips 17-21 were pooled together and CHG was extracted in 10 mL of HPLC mobile 
phase. The remaining tape stripped skin and the glass donor chambers were also extracted overnight 
in 10 mL of HPLC mobile phase. The receptor fluid time point aliquots were prepared for analysis by 
syringe filtering and vortex mixing and, if appropriate, dilution [8]. Normalisation of the drug content 
on tapes strips was conducted by using the method described in work by Reddy et al using [33]: 
 
𝐶𝑛 =
𝑚𝑛.𝜌𝑠𝑐
𝑚𝑠𝑐,𝑛
            (1) 
 
where Cn is the concentration of the drug of the nth tape strip accounting for the mass of stratum 
corneum material, which has been determined gravimetrically; 
 mn is the mass of drug in the nth tape strip 
 𝜌 sc is the density of the stratum corneum, assumed to be 1g/cm3 [34] 
 msc,n is the mass of stratum corneum on the tape strip, determined gravimetrically 
 
 
HPLC Analysis of CHG 
HPLC analysis of CHG samples was adapted from the method detailed in work by Karpanen et al. [2]. 
Analysis was conducted on a Shimadzu UCFC Modula system with an SPD M20 diode array detector 
using an isocratic mobile phase consisting of a methanol: water mixture (75:25) with 0.005 M sodium 
octane-1-sulphonate and 0.1% (v/v) triethylamine. The pH was adjusted with glacial acetic acid to pH 
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4. The flow rate was 1.5 mL per minute on a MetLab ODS-H reverse phase column (150 × 4.6 mm, 5 
μm) that was set for 40 oC. Mobile phase was used as the solvent for all CHG extractions [2]. The limit 
of detection (LOD) and limit of quantification (LOQ) were determined to be 0.050 μg/mL and 0.167 
μg/mL, respectively. The relative standard deviation (RSD) was calculated for 6 repeats of the 10 
μg/mL standard and was found to be 0.40%. For the skin assays conducted in this study the %RSD for 
each standard was <5% and R2 was 0.9999. 
 
Statistical analysis 
All data is presented as the mean ± standard error of the mean (SEM), unless otherwise stated. 
Analysis was conducted via GraphPad Prism® version 5 (San Diego, USA). Prior to statistical analysis all 
data were checked for normality using the D’Agostino-Pearson test running on GraphPad Prism 
software. To compare the mean total concentration of CHG detected within the porcine epidermis 
after the various skin pre-treatments described above a Kruskal-Wallis ANOVA test was conducted as 
the data was non-parametric, with p<0.05 representing significance. A Kruskal-Wallis ANOVA with a 
Dunn’s post-test to compare treatment groups was also performed to determine if there was a 
difference in total CHG concentrations within the receptor fluid at 24 h for the different skin pre-
treatment groups. A Kruskal-Wallis ANOVA test was used to determine whether there was a significant 
difference between the total CHG concentration extracted from the tape strips after various skin pre-
treatments with p<0.05 signifying statistical significance. Furthermore, a Kruskal-Wallis test with a 
Dunn’s post-test was also employed to determine whether there was a significant difference in CHG 
concentration within the epidermis and dermis after various skin pre-treatments. 
 
Time-of-Flight Secondary Ion Mass Spectrometry analysis of skin samples 
 
Sample preparation for ToF-SIMS analysis  
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Prior to ToF-SIMS analysis, samples were prepared and analysed using the methods reported 
previously [9, 16]. Following the Franz cell experiments the skin samples were frozen at -80oC until 
required. The frozen skin samples were mounted on a cryostat using Optimal Cutting Temperature 
embedding material. Vertical cross sections of skin (8 μm) were cut and placed on to a clean glass 
cover-slip (1 cm × 1 cm); the cover slips were first rinsed in ultra-pure water followed by methanol, 
chloroform and finally hexane before the skin sample was loaded. The 21 tape strips taken from 
diffusion cell experiments were then freeze-dried and placed on a solvent-cleaned microscope slide 
ready for analysis. 
 
ToF-SIMS analysis  
Analysis was performed using a ToF-SIMS IV instrument (IONTOF, GmbH, Münster, Germany) 
employing a Bi3+ primary ion source and a single-stage reflectron analyzer. Data acquisition and 
analysis was performed using SufaceLab 6 software. Both positive and negative spectra were acquired 
at a resolution of 256 × 256 pixels by scanning a primary beam over the sample area (500 × 500 µm). 
Charge compensation was performed by irradiation of the sample with a pulsed beam of electrons 
using an electron flood gun. Although data was collected in both positive and negative polarity, only 
the negative ion data are presented as the positive ion data, though supportive, was found to be much 
less informative. All CHG markers were chosen from spectra that were operated in the bunched mode 
[9, 16]. 
 
Statistical analysis of data  
All data shown in the ToF-SIMS study is displayed as the mean ± either SEM or SD, as stated, followed 
by the sample number. To determine whether there was a statistical significance between the 
measured CHG ingress (μm) within the skin, with and without a PAMAM dendrimer pre-treatment, a 
two-way t-test was conducted via GraphPad Prism® version 5 (San Diego, USA) after confirming the 
data was normally distributed. 
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RESULTS 
 
Recovery of CHG 
CHG is known to adsorb onto a variety of surfaces including glass, cotton wool and skin [1]. Mass 
balance experiments were carried out in all studies in line with the expectations of OECD 428 [16, 9]. 
The % of recovered CHG from each Franz cell compartment was very similar across the three 
concentrations tested (Table 1) and the variance observed suggested that the adsorption of CHG onto 
the surfaces is not concentration dependent but more likely surface area dependent. The recovery in 
all experiments was within the expected range according to OECD 428 guidelines. The percentage of 
dosed CHG that was not recovered from the glass donor chamber was ~9%, but silanisation of the 
diffusion cells did not enhance the recovery of the dosed CHG. 
Table 1. Percentage recovery of three concentrations of aqueous chlorhexidine digluconate (CHG) 
after spiking each Franz cell compartment with 100l CHG (n=3). 
 
CHG 
concentration 
Percentage recovered dose spiked onto Franz cell 
compartments after 24 hours 
 
Epidermis Adhesive tape 
strip 
Donor chamber 
1% (w/v) CH 
dosed 
88 94 93 
84 92 91 
86 94 91 
Mean + SEM 86.00 + 1.155 93.33 + 0.067 91.67 + 0.0667 
5% (w/v) CHG 
dosed 
88 91 91 
82 94 88 
81 91 93 
Mean + SEM 83.67 + 2.186 92.00 + 1.000 90.67 + 1.453 
10% (w/v) 
CHG dosed 
84 92 88 
86 97 94 
84 94 91 
Mean + SEM 84.67 + 0.667 94.33 + 1.453 91.00 + 1.732 
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The effect of PAMAM dendrimer pre-treatment on the in vitro permeation on CHG using porcine 
epidermis 
 
Table 2 summarises the results from the pre-treatment skin absorption studies. It lists concentrations 
of CHG found in skin washes, donor chamber, epidermal tissue and the receptor fluid after the 24 h 
duration of the experiments. Table 2 also lists the rate of absorption (flux values) associated with each 
experiment. Results are shown for four experiments; pre-treatment as a control (with saline as the 
control) and 0.5, 1.0 and 10.0 mM solutions of the G3-PAMAM-NH2 dendrimer.
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Table 2. Compartmental diffusion cell data and rates of absorption over of CHG 24 h (0 - 12 h; 15 - 24 h and 0 - 24 h) after a skin pre-treatment of G3-
PAMAM-NH2 dendrimer (0.5 – 10.0 mM, plus control). 
 
 
Sample Control sample (no dendrimer pre-treatment) 
(n=15) 
Pre-treatment (0.5 mM) 
(n=19) 
Pre-treatment (1.0 mM) 
(n=24) 
Pre-treatment (10 mM) 
(n=24) 
CHG (g/cm2) % of applied dose CHG (g/cm2) % of applied dose CHG (g/cm2) % of applied dose CHG (g/cm2) % of applied dose 
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM 
Donor 
chamber 
815.129 154.935 10.354 1.967 307.786 59.483 3.909 0.755 700.350 96.384 8.890 1.224 617.035 136.620 7.836 1.735 
Skin wash 
 
4080.063 398.892 51.817 5.066 4515.081 301.075 57.342 3.824 3924.292 291.115 49.839 3.697 4419.776 285.820 56.131 3.630 
Epidermis 
 
1030.668 130.917 13.089 1.662 1202.763 177.213 15.275 2.251 986.226 118.160 12.525 1.501 1421.675 187.069 18.055 2.376 
Receptor 
fluid 
3.226 1.622 0.041 0.020 92.013 34.490 1.169 0.438 47.324 12.150 0.601 0.154 82.912 16.681 1.053 0.212 
Total 
recovered 
5929.086 686.366 75.299 8.715 6117.643 572.261 77.694 7.268 5658.192 517.809 71.855 6.576 6541.388 626.19 83.075 7.953 
 
 
 Control sample (no dendrimer pre-treatment) 
(n=15) 
Pre-treatment (0.5 mM) (n=19) Pre-treatment (1.0 mM) (n=24) Pre-treatment (10 mM) (n=24) 
Absorption rate (g/cm2/h) Absorption rate (g/cm2/h) Absorption rate (g/cm2/h) Absorption rate (g/cm2/h) 
0-12 h 
 
15-24 h 0-24 h 0-12 h 15-24 h 0-24 h 0-12 h 15-24 h 0-24 h 0-12 h 15-24 h 0-24 h 
Mean 
0.0164 
 
0.219 0.097 0.395 1.618 0.890 0.174 1.100 0.612 0.477 1.525 0.980 
SEM 
 
0.0126 0.103 0.045 0.254 0.402 0.221 0.063 0.250 0.139 0.137 0.318 0.193 
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Table 2 shows that the majority of applied CHG (approximately 60%) remains on the skin surface or 
the donor compartment at the end of the experiment. Approximately 13 – 18% of the applied dose is 
found in the epidermis, including the superficial stratum corneum, with a very small amount, of 
approximately 0.04 – 1.20%, found in the receptor compartment of the diffusion cell. Flux was found 
to be biphasic in many cases and the absorption rates for 0 – 12 hours and 15 – 24 hours are listed in 
Table 2, along with the overall absorption rate for the 24 hour experiments. 
 
The trends in CHG flux are summarised in Figure 1. In Figure 1 (a) the diffusion profiles clearly illustrate 
the biphasic release profiles and the distinction between the control pre-treatment experiment and 
the dendrimer pre-treatments (0.5, 1.0 and 10.0 mM). The concentration profiles for CHG were very 
similar across all PAMAM dendrimer concentrations tested up to a time period of 9 h. The largest 
concentration increase was observed in the 12-24 h time period. Figure 1 (b) shows the concentration 
of CHG extracted from the epidermis after 24 h for all four skin pre-treatments. Though the 10 mM 
G3-PAMAM-NH2 dendrimer skin pre-treatment yielded the highest CHG deposition within the 
epidermis, no significant difference was observed between the CHG concentrations (μg/cm2) 
extracted from the epidermis for the four skin pre-treatment groups (Kruskal Wallis ANOVA, p>0.05). 
 
Figure 1. Results of diffusion cell studies for CHG: (a) concentration of CHG (mean ± SEM) detected by 
HPLC within the receptor fluid over a 24 h time period after a range of skin pre-treatments (0.5mM, 
n=19; 1mM, n=24; 10mM, n=24) and control (0.9% NaCl, n=15); (b) concentration of CHG (mean ± 
SEM) within the epidermis at 24 h after a range of skin pre-treatments; (c) concentration of CHG (mean 
± SEM) absorbed within the receptor fluid at 24 h after various skin pre-treatments.  
a) b) c) 
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The total concentration of CHG (as mean ± SEM) detected within the receptor fluid at 24 h for a range 
of PAMAM dendrimer pre-treatments is shown in Figure 1 (c). The data was normally distributed and 
a Kruskal Wallis ANOVA with a Dunn’s post-test confirmed that for all three concentrations of G3-
PAMAM-NH2 dendrimer skin pre-treatment tested, the total concentrations of CHG absorbed within 
the receptor fluids at 24 h were significantly different (p< 0.0001) from the physiological saline pre-
treated skin (Figure 1 (c)). No significant difference in the absorption of CHG at 24 h was observed 
between the different PAMAM dendrimer concentrations tested (p>0.05). 
 
Franz diffusion cell studies using tape stripping to profile CHG within porcine dermatomed skin 
 
Tape stripping studies were carried out for the 1.0 mM G3-PAMAM pre-treatment solution. A number 
of observations during this procedure are worthy of note as they contextualise the findings of an 
established method. Approximately following the 6th tape strip the skin became very moist, suggesting 
the removal of interstitial fluid as well as stratum corneum on the tape strips which was therefore 
recorded within the mass data [32]. The moisture attributed to interstitial fluid also caused the 
epidermis to tear during the tape stripping process, typically after the template had been placed over 
the dose area and pressure applied to the tape strip. Due to the tearing of the epidermis 21 tape strips 
were not obtained from each experiment. Details of the number of tape strips that were successfully 
removed are presented in the annotations associated with Table 3 and Figure 2 where relevant. 
 
 
Table 3. Compartmental diffusion cell data of CHG concentration for control skin sample pre-
treatment (n=21), vehicle control skin pre-treatment (n= 4) and 1 mM G3-PAMAM-NH2 dendrimer skin 
pre-treatment (n=18).  
 
Sample CHG concentration following a 
control  
CHG concentration following a vehicle 
control  
CHG concentration following a G3-
PAMAM-NH2 dendrimer  
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skin pre-treatment 
(n = 21) 
skin pre-treatment 
(n = 4) 
 
(1 mM) skin pre-treatment 
(n = 18) 
CHG (g/cm2) 
  
% of applied 
dose 
CHG (g/cm2) 
 
% of applied 
dose 
CHG (g/cm2) 
 
% of applied 
dose 
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM 
Donor 
chamber 
 
434.410 85.970 5.517 1.092 495.603 166.610 6.294 2.116 460.305 86.630 5.846 1.100 
Skin 
wash 
 
 
4416.08
9 
516.50
4 
56.08
5 
6.560 
3812.01
2 
204.405 
48.41
3 
2.595 
3142.01
1 
401.605 
39.90
4 
5.100 
Tape 
strips 
 
1298.03
3 
259.40
0 
16.48
5 
3.294 
1483.08
0 
540.783 
18.83
5 
6.868 
2043.09
5 
421.683 
25.94
7 
5.355 
Epidermi
s / 
dermis 
 
503.100 92.854 6.390 1.180 716.700 166.350 9.102 2.113 
1077.50
2 
148.991 
13.68
4 
1.892 
Receptor 
fluid 
 
0.017 0.017 
0.000
2 
0.000
2 
0.670 0.355 0.009 0.005 0.937 0.205 0.012 0.002 
Total 
recovere
d 
 
6651.64
9 
954.74
5 
84.47
2 
12.12
6 
6508.06
5 
1078.50
3 
82.65
3 
13.69
7 
6723.85
0 
1059.11
4 
85.39
3 
13.44
9 
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Figure 2. Figure 2. Tape stripping experiments from diffusion cell studies: (a) graph illustrating the 
cumulative mass of SC material on individual tape strips for various skin pre-treatments. Cumulative 
mass (± SEM) of SC material (mg) as a function of tape strip number. For CHG dosed alone n=21, For 
PAMAM dosed n= 13 and for vehicle control n=3; (b) concentration profile of CHG detected on each 
tape strip;(c) concentration (presented as mean ± SEM) of CHG per mg of SC material weighed 
gravimetrically (µg/mg) after stripping dermatomed skin following a pre-treatment for 24 h with a 1 
mM PAMAM solution of G3-PAMAM-NH2 dendrimer (n=13), vehicle control (n=3) and CHG dosed 
alone (n=21). (d) data showing the total CHG (mean ± SEM) extracted from the tape strips (µg/cm2) 
for each of the dermatomed skin pre-dose treatments; (e) the mean total concentration (µg/cm2) of 
CHG extracted from the remaining epidermis and dermis after the SC had been removed by tape 
stripping. A non-parametric Kruskal-Wallis test was conducted with a Dunn’s post-test.  
 
 
Figure 2(a) shows the mean cumulative mass of stratum corneum material as a function of tape strip 
number. This shows that similar amounts of material were collected from the pre-treatment control 
skin samples (solvent only as pre-treatment; 12.240 ± 2.621 mg at tape strip 20, cumulative) than for 
the G3-PAMAM pre-treated control sites (solvent-PAMAM solution, no CHG; 14.078 ± 3.268 mg at 
tape strip 19). The highest mass of stratum corneum material was collected from samples pre-treated 
with PAMAM dendrimer and then with CHG (2% w/w solution; 23.643 ± 8.113 mg at tape number 15, 
cumulative).It was also noted that fewer tape strips were consistently taken from the PAMAM 
dendrimer pre-treated skin as they were prone to being torn during the sample collection procedure. 
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Figure 2(b) shows the profile of CHG found in the tape strips for example the superficial layers of the 
stratum corneum (tape strips 1-3) exhibited the highest concentration of CHG and lower 
concentrations of CHG were found as depth into the skin increased. The PAMAM dendrimer pre-
treated skin exhibited the highest amount of CHG. For example, for tape strips 7-10 the mean 
concentration of CHG extracted from the tape strips was 179.182 ± 63.057 μg/mL, 132.020 ± 6.353 
μg/mL and 99.874 ± 23.293 μg/mL for PAMAM dendrimer pre-treated, vehicle control and 
physiological saline pre-treated skin samples, respectively. This is a 20-fold decrease in CHG 
concentration when compared to tape strip 1, but is still considered as a high biocidal concentration.  
Tape strips 7-10 showed a similar trend to tape strip 1 in that the PAMAM dendrimer pre-treated skin 
demonstrated the highest concentration of CHG. Due to the inconsistent nature of deeper tape strip 
collection, meaningful comparisons between the CHG concentrations at the higher tape strip numbers 
were not feasible due to the low sample number of the higher tape strips which was a result of tearing 
of the epidermis. Accounting for gravimetric adjustments (Equation 1), Figure 2(c) shows the 
concentration of CHG per mg of stratum corneum material removed onto the tape strips. This profile 
is substantially different from Figure 2(b), appearing less regular, and is most likely due to the issue of 
moisture associated with collecting the tape strips, usually from tape strip number 6 onwards. 
 
Table 3 presents the mean absorption and distribution of CHG within the skin following a pre-
treatment of physiological saline. Approximately 5.5% of the dosed CHG was extracted from the glass 
donor chamber, which is comparable to the data presented in Table 1. A total recovery of ~85% was 
achieved, which is an increase of ~10% when compared to the epidermal study, and is due to an 
increased recovery of CHG from the skin due to extraction of CHG using tape strips from the stratum 
corneum. Similarly, absorption and distribution of CHG following pre-treatment without the PAMAM 
dendrimer is also shown in Table 3. A similar recovery profile to earlier experiments (Table 1) was 
found, as is the recovery of CHG within the skin wash. The mean percentage of applied dose recovered 
from the tape strips, which are assumed to have removed the entire stratum corneum, was 1483.080 
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± 540.783 μg/cm2. The total mean concentration of CHG recovered from the tape strips, 
epidermis/dermis, and receptor fluid for the vehicle control was 2200.45 ± 707.488 μg/cm2, which is 
higher than the physiological saline but not significantly different (p>0.05). 
 
The percutaneous absorption and distribution for CHG permeation with 1 mM G3-PAMAM-NH2 
dendrimer solution pre-treatment are shown in Table 3. There was an increase in the percentage of 
applied dose of CHG extracted from the tape strips, and the stratum corneum, when compared to the 
physiological saline and vehicle control experiments. The mean percentage of applied dose recovered 
from the tape strips was 2043.095 ± 421.683 μg/cm2, which is the highest concentration of CHG 
recovered from the stratum corneum within the skin dermatome studies. The mean concentration of 
CHG absorbed within the tape strips, remaining epidermis/dermis and CHG recovered from receptor 
fluid was 3.12 ± 0.57 mg/cm2. Total mean recovery of CHG for this experiment was ~85%. 
 
When the skin was pre-treated with a 1 mM solution of G3-PAMAM-NH2 a higher concentration of 
CHG was extracted from the total number of tape strips, which is assumed to represent the stratum 
corneum. An increased mean CHG concentration of 2.04 ± 0.42 mg/cm2 was extracted from the tape 
strips following a PAMAM dendrimer pre-treatment, compared to the lower concentrations of 1.48 ± 
0.54 mg/cm2 following a vehicle solution pre-treatment and 1.30 ± 0.26 μg/cm2 was the mean CHG 
total extracted from all tape strips for physiological saline skin pre-treatment (Figure 2(d)). The 
PAMAM dendrimer pre-treatment yielded the highest concentration of CHG from the total number of 
tape strips compared to the treatment groups without the presence of the PAMAM dendrimer. This 
perceived enhancement effect is not statistically significant due to the high inherent variability 
observed within this study. Furthermore, Figure 2(e) shows the mean concentration of CHG within the 
remaining epidermal and dermal tissue following tape stripping. The CHG concentration within the 
epidermis and dermis shows the same trend of G3-PAMAM-NH2>vehicle control>negative control pre-
treated as that shown in Figure 2(d).  After PAMAM dendrimer pre-treatment the concentration of 
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CHG within the skin was significantly higher than that of the skin pre-treated with physiological saline. 
No statistical difference was observed between the vehicle control and the negative physiological 
saline control (p>0.05).  
 
ToF-SIMS analysis of chlorhexidine digluconate treated porcine skin cryo-sections.  
 
A series of cryosectioned skin that included pre-treated with G3-PAMAM-NH2  or an untreated control 
followed by CHG application were analysed using ToF-SIMS. The identification of a characteristic series 
of ion species, as reported in previous studies, [9, 16] were found which were attributed to CHG, 
including Cl-, C7H4N2Cl- and M-H-. The embedding material for cryo-sectioning, OCT, was also analysed 
in parallel as a reference material and there was no peak overlap. Although several ions were found 
which were indicative of CHG, the C7H4N2Cl- ion will be used exclusively as it has both relatively high 
chemical specificity and ion intensity enabling chemical imaging. The secondary ion images of the skin 
samples pre-treated with the PAMAM dendrimer show a significant increase in ion intensity 
throughout the skin strata for the CHG marker, C7H4N2Cl-, compared to CHG dosed without a 
dendrimer pre-treatment (Figure 3(a)). The mean permeation distance of CHG into the skin, as 
measured by the intensity of the C7H4N2Cl- signal observed in Figure 3(a),  was found to be 32.22 ± 1.41 
μm and 47.56 ± 3.98 μm for PAMAM dendrimer untreated and PAMAM dendrimer pre-treated skin 
respectively. A comparison of this skin ingress is shown in Figure 3(b), which shows a significantly 
greater depth penetration by CHG into the skin following a pre-treatment with the PAMAM dendrimer 
(T test; t=4.07; p<0.001).  
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Figure 3(a). Secondary ion images of C7H4N2Cl- for a pre-treatment of G3-PAMAM-NH2 (10 mM, 0.2 mL 
dose) followed by an application of 2 % CHG (w/v) as compared to no PAMAM pre-treatment onto 
porcine dermatomed skin (400 µm thick). Field of view is 500 × 500 µm (b) Data showing the depth 
permeated by CHG (2 % w/v) with and without a G3-PAMAM-NH
2 
(10 mM, 0.2 mL) pre-treatment as 
measured using line profiles generated from the data shown in Figure 3(a).  
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ToF-SIMS analysis of CHG distribution on tape strips from PAMAM dendrimer pre-treated porcine 
skin 
 
ToF-SIMS was previously used both for the analysis of tape stripped samples as well as 
cryomicrotomed cross-sections whereby the observation of CHG in both acted as a cross-validation of 
the methods used for the analysis of CHG within porcine skin [9, 16]. Figure 4 shows the secondary 
ion images of C7H4N2Cl- for individual tape strips analysed by the ToF-SIMS. An even distribution of 
CHG can be observed across each tape strip up until tape strip 14 where it then becomes more 
heterogeneous (Figure 4). The application of CHG alone demonstrates the decrease in CHG with 
increasing tape strip number (representing an increase in depth) removed. There is also a decrease in 
the amount of stratum corneum removed with increasing tape strip number (Figure 4). The secondary 
ion intensity data produced by the ToF-SIMS analysis of the tape strips were used to observe the 
enhanced distribution and permeation of CHG following a G3-PAMAM-NH2 pre-dose treatment 
(Figure (5)). The skin pre-treated with the PAMAM dendrimer exhibited a greater intensity of the CHG 
marker across the upper skin strata, with C7H4N2Cl- being observed throughout the stratum corneum 
(Figure 5).  Figure 5 demonstrates that permeation of CHG following dendrimer pre-treatment is 
significantly greater, and that CHG penetrates into the stratum corneum, compared to permeation in 
the absence of a dendrimer pre-treatment. Without a PAMAM dendrimer pre-treatment the CHG 
signal decreases markedly at tape strip 13 however after a PAMAM dendrimer pretreatment the CHG 
signal is still strong showing elevated CHG concentrations in the deeper layers of the stratum corneum. 
 
 
 
 
       Ctrl 1 Ctrl 2 Strip 3 
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Figure 4. ToF-SIMS secondary ion images of C7H4N2Cl- for 21 consecutive tape strips taken from 2% 
CHG (w/v) dosed porcine dermatomed skin (400 μm thick) and two tape strips taken from an 
untreated control, field of view 500 x 500 µm. Image adapted from [16]. 
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Figure 5.  C7H4N2Cl- ion intensity assigned to CHG, for 20 consecutive tape strips taken from CHG dosed 
alone (2 % w/v) to porcine skin (n=4 ± SD) and to G3-PAMAM-NH2 (10 mM, 0.2 mL dose, 24 h) pre-
treated porcine skin then dosed with CHG dosed (2 % w/v) (n=4 ± SD).  
 
DISCUSSION 
 
Penetration enhancement effect of G3-PAMAM-NH2 analysed by HPLC 
The results of the Franz cell studies clearly indicate that the skin permeation of CHG increased by up 
to 30-fold, when preceded by a PAMAM dendrimer pre-treatment (Table 2). Enhancement was not 
concentration dependent but showed a similar effect over the concentration range examined in this 
study, relative to control (Figures 1 (b) and (c)). The lack of a clearly defined dose-response in this case 
is most likely due to the high variability observed in the diffusion cell studies, which might be partly 
attributed to inherent variation associated with such experimental protocols, but also to the recovery 
of CHG (Table 1) which, was often variable. This would likely be due to the number of cationic amine 
groups on the CHG able to bind to tissue and glassware and this may have influenced the statistical 
significance of the outcome. Nevertheless, the results obtained herein clearly demonstrate that the 
pre-treatment of skin with the PAMAM dendrimer significantly increases skin permeation of CHG 
observed in in vitro diffusion cell studies. A similar effect has been reported previously for 5-
fluorouracil following pre-treatment of the skin with a G4-PAMAM-NH2 dendrimer [26]. In this study 
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the proposed mechanism of action / enhancement was to the interaction of cationic dendrimers with 
the skin lipid bilayers, where reductions of skin resistance were observed with a range of dendrimer 
molecules, suggesting that the dendrimers chemically altered the composition of skin lipid bilayers.  
Other studies have shown a 4-fold increase in the skin permeation of tamsulosin hydrochloride 
following dendrimer pre-treatment [21]. The authors also reported that a similar enhancement was 
not observed for two other drugs, namely ketoprofen and clonidine, and suggested that the 
electrostatic interaction between the drug and the dendrimer was key to its enhancement effect. In 
addition, it was also suggested that these enhancement effects have been attributed to dendrimer 
aggregation at high concentrations [35]. 
 
The exact mechanism of enhanced topical and transdermal drug delivery by dendrimers is still 
unknown but is suggested to be attributed to action as a drug release modifier thereby increasing drug 
dissolution, preferential accumulation within the appendages of the skin and impairing the barrier 
function of the stratum corneum [23].  PAMAM dendrimers have been suggested as a drug release 
modifier with a cyclodextrin-like mechanism in that they can act as a carrier system for the lipophilic 
drug indomethacin (log P 4.3) [21]. As with PAMAM dendrimers, lipophilic drugs form an electrostatic 
or hydrophobic complex with cyclodextrins that then increases the solubility of a drug within an 
aqueous vehicle. This then results in an increase in the concentration of drug that can partition into 
the stratum corneum [36].  
 
This is the first study to investigate PAMAM dendrimers as a topical penetration enhancer of an 
antiseptic with the aim of increasing the exposure of the bacteria in skin to the CHG. Pre-treatment of 
the skin with G3-PAMAM (0.5 – 10.0 mM) resulted in an increase not only to the rate of CHG skin 
permeation, but also caused a significant decrease in its lag time to achieve steady-state permeation 
much quicker when compared to CHG permeation without PAMAM pre-treatment as shown in Table 
2. It is therefore reasonable to comment that PAMAM dendrimer facilitated skin absorption would 
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result in a much faster and hence more effective action. An efficacious antiseptic has been described 
by the Food and Drug Administration (FDA) for healthcare antiseptic drug products as “a fast-acting 
[rapidly kills microorganisms], broad spectrum [kills a wide variety of microorganism species], 
persistent [suppresses regrowth of remaining microorganisms], antiseptic containing preparation that 
significantly reduces the number of microorganisms on intact skin” [38]. However, while it is clear that 
CHG possesses these attributes the compound poorly penetrates the skin. Thus, the application of 
PAMAM dendrimers to topically applied systems may reduce the lag time and better facilitate the 
antisepsis of the deeper skin layers, as greater permeation would occur within a shorter time frame. 
Such a capability therefore addresses the first requirement of the FDA monograph “more effectively”, 
potentially offering increased efficacy of the antibacterial agent when it is applied to the skin with a 
dendrimer.  
 
It was observed throughout the diffusion cell experiments that, once the vehicle had evaporated (ca. 
3-6 h), a viscous and adhesive layer of G3-PAMAM-NH2 dendrimer was deposited across the skin 
surface. This has been attributed to the highly hygroscopic nature of PAMAM dendrimers [17] that 
extract water from the surrounding environment to exist in a gel-like state. Thus, a dense PAMAM 
dendrimer layer distributed across the skin surface may reduce the TEWL from the skin, causing skin 
hydration and thereby acting as a possible mechanism of enhancement for the skin permeation of 
CHG. Occlusion of the skin leading to increased hydration has been a known mechanism of skin 
penetration for certain compounds for many years [38, 39]. The water content of the stratum corneum 
is typically 15-20% (dry weight) but can increase up to 400% of the dry weight of tissue under occlusion 
and increased humidity [40]. Occlusion has been utilised as a permeation enhancer for a range of 
therapeutics and biomolecules, most commonly in transdermal skin patches, but also in other 
systems, including fluorescein isothiocyanate-bovine serum albumin [41] and 14C acetylsalicylic acid 
[42]. On hydration of the skin, corneocytes of the stratum corneum become highly swollen increasing 
the cell volume [43]. Hydrating the skin for permeation enhancement of a wide range of therapeutics 
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has been used for many years, but it does not enhance the skin permeation of all compounds [44, 45]. 
Hence other mechanisms for improving drug delivery across the skin – such as we have presented 
here – provide an alternative strategy.  
 
There was an increase in CHG concentration within the epidermis and dermis when the PAMAM pre-
treated skin was compared to the physiological saline pre-treated skin for in vitro diffusion cell studies 
(Figure 1 (b) and (c)). These results indicate that the PAMAM dendrimer pre-treatment increases the 
deposition of CHG within not only the superficial layers of the stratum corneum but also the epidermis 
and dermis. The aim of this study was to increase the penetration and retention of CHG within the 
skin and this has been demonstrated within the epidermis and percutaneous absorption studies 
presented herein. An increase in the deposition of CHG within the skin may therefore improve 
antibacterial efficacy by increasing the exposure of opportunistic pathogens to CHG [2]. 
 
In addition to the improvement in limit of detection offered by ToF-SIMS, compared to HPLC-facilitated tape 
stripping the ToF-SIMS method is able to provide additional information on the permeation process. For 
example, one additional important consideration is that the ToF-SIMS method provides evidence of the 
uniformity of delivery into the skin, something that is complementary and additional to the tape-stripping 
studies. It demonstrates that chlorhexidine is not penetrating via specific channels, such as skin appendages 
or via small, localised areas and that permeation is moving uniformly through the skin. The cross-sectioned 
data also allows a visualisation of permeation that could allow a correlation with the different physiological 
layers in the skin in greater detail. 
 
For example, Figure 7 shows that, in term of physiological correlation, PO is well known to be more prevalent 
in the epidermis than the stratum corneum. The PO2- image thus denotes the end of the stratum corneum and 
so allows this strata to be accurately observed. It also shows that this strata contains a substantial amount of 
chlorhexidine and that significantly less chlorhexidine is present in the deeper skin tissues. 
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Figure 7. Co-localisation of chlorhexidine in the skin with skin structures, identified by the presence of 
PO2- fragments, which are normally localised to the stratum corneum. 
 
 
Penetration enhancement effect of G3-PAMAM-NH2 analysed by ToF-SIMS 
 
Despite issues with the variation of tissue and the complexities of fully characterising the skin 
permeation of exogenous chemicals, correct use of the OECD 428 in vitro Franz diffusion cell approach 
provides a good surrogate for dermal absorption in man. This study supports  the previously reported 
use of the ToF-SIMS technique in characterising the actual chemistry in skin during the absorption 
process. This is not, of course, a replacement for diffusion cell studies but it is certainly a valuable 
complementary technique which allows visualisation of a permeant within the skin cross-sections, 
allows the acquisition of real permeation depth values including those which are relevant, when 
compared to histological samples, to skin structural features and which provides a semi-quantitative 
assessment of permeation into skin.   
 
Skin diffusion cell experiments in this study have shown that pre-treatment of the skin with 
dendrimers significantly enhanced CHG absorption. This is clearly supported by the ToF-SIMS 
experiments, where the permeation enhancement could also be visualised (Figure 3). While CHG could 
be readily detected by the ToF-SIMS through unique fragment identification, those fragment ions 
detected that correspond to the dendrimer were not sufficiently unique to be distinguished from the 
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endogenous skin components. This is due to G3-PAMAM dendrimers being constituted of polymeric 
branches of amides and carboxyl groups which appear in the skin in abundance. As such no comment 
on the skin permeation of G3-PAMAM dendrimers can be made. However, a clear intensity increase 
of the CHG markers within the upper skin strata was observed which was attributed to the penetration 
enhancement effect of the PAMAM dendrimer. When the PAMAM dendrimer-treated skin is 
compared to the skin treated with CHG alone, the considerable penetration and deposition 
enhancement is clearly evident. We have also showed a significant (t=4.07, p<0.001) penetration 
depth increase of CHG following PAMAM pre-treatment which indicates that permeation had 
progressed approximately 15 μm further into the skin compared to CHG delivery in the absence of 
PAMAM enhancement. 
 
  
33 
 
CONCLUSIONS 
 
The results of this study indicate that a pre-treatment of the skin with G3-PAMAM dendrimers 
significantly increases the amount and depth of permeation of CHG into porcine skin in vitro. This 
observation could be of great significance in terms of the efficiency and effectiveness of antibacterial 
treatment and may potentially be extrapolated to other topical products. While the mechanism for 
enhanced dermal delivery is still unclear, requiring further investigation, it is proposed that the 
PAMAM dendrimer enhances dermal absorption either by barrier lipid disruption or by occluding the 
skin surface. The ex vivo diffusion cell experiments in pig skin have been complimented by the ToF-
SIMS method, specifically adding the visualisation of the drug in the skin layers. This allows the 
potential for mapping the co-localisation of specific permeants with skin structures (i.e. the proximity 
of permeants to skin layers, such as the stratum corneum) thus providing a greater ability to 
characterise penetration enhancers, drug delivery systems, skin absorption and to understand the 
mechanism of permeation. The sensitivity of the technique also allows for a more accurate depth 
profile of CHG permeation within the skin to be obtained.  
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